News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Oil jumps over 3% after Iran says the Strait of Hormuz is closed, lifting the dollar and pressuring global markets.
  • U.S. futures and Asian equities slip as Middle East strikes and Strait uncertainty raise risk ahead of heavy Q2 earnings.
  • Wolfe Research warns H2 2026 congressional deadlines, tariff shifts and regulatory rulemakings could materially affect manufacturing, financials and energy.
  • EU foreign ministers will discuss trade restrictions on West Bank settlements, but deep divisions make a decisive vote unlikely.
  • Australia's ASIC fined Deutsche Bank A$2 million for widespread misreporting of OTC derivatives between Oct 2024 and Aug 2025.
  • Similarweb signals early LLM contract wins could re-accelerate revenue and support a stock recovery if proofs convert to paid deals.

Latest Articles

Nuvei to Buy Payoneer for $2.75 Billion in Cash; Shares Rise in Premarket

Nuvei to Buy Payoneer for $2.75 Billion in Cash; Shares Rise in Premarket

Payoneer Global Inc. (NASDAQ:PAYO) agreed to be acquired by payments firm Nuvei in a $2.75 billion all-cash transaction valued at $7.40 per share. Payoneer shares climbed 3.4% in premarket trading as the boards of both companies approved the deal. The combined company is projected to generate roughly $3 billion in annual revenue and to process more…

ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera’s Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis)

ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera’s Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis)

Entera Bio Ltd. presented encouraging Phase 1 clinical data at ENDO 2026 demonstrating that their single tablet oral anabolic therapy, EB613, achieved pharmacokinetic and pharmacodynamic profiles comparable to the injectable standard treatment Forteo4. EB613 was well-tolerated with a favorable safety profile and was preferred by study participants…

Wearable Devices to Unveil GenAI-Powered Intent-Based Interface Platform and Next-Gen Mudra Pro Flagship at AWE 2026

Wearable Devices to Unveil GenAI-Powered Intent-Based Interface Platform and Next-Gen Mudra Pro Flagship at AWE 2026

Wearable Devices Ltd. announced its showcasing of a comprehensive neural input ecosystem at the Augmented World Expo 2026, highlighting its next-generation Mudra Pro hardware platform and Mudra Studio software platform leveraging generative AI. These innovations enable ultra-low latency, touchless, gesture-based controls for AI, augmented reality, …

Novo Nordisk Reclaiming Growth: A Long Trade on GLP-1 Momentum

Novo Nordisk Reclaiming Growth: A Long Trade on GLP-1 Momentum

Novo Nordisk is trading well below its 52-week high despite a dominant position in GLP-1 therapies and fresh regulatory wins for an oral Wegovy tablet. The balance sheet, dividend yield, and a reasonable P/E provide a constructive backdrop. This trade idea proposes a long entry at $44.00 with a $60.00 target over the next 180 trading days and a sto…

BlockchAIn Announces Corporate Name Change to AIB Data Centers Inc.

BlockchAIn Announces Corporate Name Change to AIB Data Centers Inc.

BlockchAIn Digital Infrastructure, trading as AIB on NYSE American, announced a corporate name change to AIB Data Centers Inc. reflecting its strategic pivot from digital asset infrastructure to AI and high-performance computing data center development and operations. The name change will be effective June 25, 2026, with trading under the new name …

Fate Therapeutics Appoints Laura Hamill to Board of Directors

Fate Therapeutics Appoints Laura Hamill to Board of Directors

Fate Therapeutics appoints Laura Hamill, a seasoned global biopharma executive with extensive commercial and strategic experience, to its Board as it advances its iPSC-derived cellular immunotherapy pipeline towards later-stage clinical development and commercialization. This move is expected to bolster the company's transition to a commercial-stag…

RBB Bancorp Announces Authorized Common Stock Repurchase Plan and Partial Redemption of Subordinated Debt

RBB Bancorp Announces Authorized Common Stock Repurchase Plan and Partial Redemption of Subordinated Debt

RBB Bancorp announced that its board authorized a stock repurchase plan to buy back up to 1 million shares, approximately $25 million or 6% of outstanding shares, through June 30, 2028. Concurrently, the company plans to redeem $40 million of its 4.0% Fixed to Floating Rate Subordinated Notes due 2031, reflecting a strong capital position and liqui…

Patriot Bank Expands High Net Worth Banking Platform in Greenwich, CT

Patriot Bank Expands High Net Worth Banking Platform in Greenwich, CT

Patriot Bank, a subsidiary of Patriot National Bancorp (NASDAQ: PNBK), is expanding its high-net-worth banking platform in Greenwich and Fairfield County, Connecticut. The bank has appointed seasoned private banking executives, including DeWitt Hutchins as Connecticut Market President, and plans to enhance its Mason Street branch with upgraded faci…

Splash Beverage Group Invests in Avicanna, a Leading Cannabinoid Biopharmaceutical Platform, Advancing Its Transformation Into Cannabinoid Healthcare

Splash Beverage Group Invests in Avicanna, a Leading Cannabinoid Biopharmaceutical Platform, Advancing Its Transformation Into Cannabinoid Healthcare

Splash Beverage Group completed a strategic investment of CDN$300,000 in Avicanna Inc., a leading cannabinoid biopharmaceutical company, to support its shift towards a cannabinoid-based health, wellness, and healthcare platform. The investment aligns with Splash's goal to leverage Avicanna's clinical-stage pharmaceutical assets, intellectual proper…

Alto Ingredients, Inc. Completes Transaction to Monetize All 2025 45Z Clean Fuel Production Tax Credits

Alto Ingredients, Inc. Completes Transaction to Monetize All 2025 45Z Clean Fuel Production Tax Credits

Alto Ingredients, Inc., a US-based producer of specialty alcohols and renewable fuels, completed a sale of its 2025 Section 45Z Clean Fuel Production Tax Credits for approximately $8.9 million in cash. The transaction aligns with the company's strategy to monetize tax credits generated from its low-carbon ethanol production facilities, providing a …

Jet.AI Announces New Record Date for Distribution of SpinCo Shares in Connection with Proposed flyExclusive Transaction

Jet.AI Announces New Record Date for Distribution of SpinCo Shares in Connection with Proposed flyExclusive Transaction

Jet.AI Inc. announced June 25, 2026 as the new record date for stockholders eligible to receive shares of SpinCo in connection with its proposed merger with flyExclusive. The transaction is pending stockholder approval, with the special meeting reconvening on June 23, 2026. Proxy advisory firms recommend voting for the deal, but completion remains …

Conexeu Expands Board, Executive, and Advisory Leadership With Five Appointments Post Nasdaq Listing

Conexeu Expands Board, Executive, and Advisory Leadership With Five Appointments Post Nasdaq Listing

Conexeu Sciences Inc., a Nasdaq-listed biotechnology company specializing in regenerative tissue therapies, announced five key leadership appointments including additions to its Board of Directors and the naming of a new Chief Commercial Officer. These leadership enhancements aim to strengthen the company's commercial and strategic capabilities as …

Cadrenal Therapeutics Advances Multi-Indication Strategy for CAD-1005; Launches Phase 2a Acute Kidney Injury (CSA-AKI) Clinical Plan to Accelerate Pharma Partnering at Upcoming BIO 2026

Cadrenal Therapeutics Advances Multi-Indication Strategy for CAD-1005; Launches Phase 2a Acute Kidney Injury (CSA-AKI) Clinical Plan to Accelerate Pharma Partnering at Upcoming BIO 2026

Cadrenal Therapeutics announced plans to initiate a Phase 2a proof-of-concept clinical trial for its drug candidate CAD-1005, targeting prevention of Acute Kidney Injury (AKI) associated with cardiac surgery (CSA-AKI). This expands the potential application of CAD-1005, which is already in late-stage development for heparin-induced thrombocytopenia…

QTREX Quantum’s AME Technology Achieves 97% Yield Validation at One of the Largest U.S. Interconnect Manufacturers

QTREX Quantum’s AME Technology Achieves 97% Yield Validation at One of the Largest U.S. Interconnect Manufacturers

QTREX Quantum Ltd. announced a major production milestone as one of the largest U.S.-based interconnect manufacturers adopted QTREX's Additively Manufactured Electronics (AME) technology for full production after extensive validation, achieving a 97% yield rate. This advancement marks QTREX's readiness for demanding manufacturing environments and s…

Aeries Technology Secures Strategic GCC Advisory Mandate with Leading Global Tax and Financial Advisory Platform

Aeries Technology Secures Strategic GCC Advisory Mandate with Leading Global Tax and Financial Advisory Platform

Aeries Technology has secured a strategic advisory engagement from a leading global tax and financial advisory firm to support the expansion of its India-based Global Capability Center (GCC) in a Tier-II city. This reflects a growing corporate trend of expanding GCCs beyond traditional metro areas to leverage deeper talent pools and improved operat…